New drug trial aims to slow liver disease in rare bile duct condition

NCT ID NCT07387549

Recruiting now Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This Phase 3 study tests whether the drug elafibranor can slow liver damage in adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts. About 350 participants will receive either elafibranor or a placebo daily for several years. The main goal is to see if the drug delays disease progression or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elafibranor (a drug taken as a tablet)
What this could lead to: If it works, this could provide a new treatment to slow liver damage and delay the need for a transplant in people with primary sclerosing cholangitis.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may not prove more effective than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cholangitis, Sclerosing primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SCLEROSING CHOLANGITIS

Contacts and locations

Locations

American Research Corporation at The Texas Liver Institute
RECRUITING

San Antonio, Texas, 78215, United States
Arizona Liver Health
RECRUITING

Chandler, Arizona, 85224, United States
Gastrointestinal Associates of Northeast Tennessee
RECRUITING

Johnson City, Tennessee, 37604, United States
Liver Associates of Texas, P.A.
RECRUITING

Houston, Texas, 77030, United States
Peak Gastroenterology Associates
RECRUITING

Colorado Springs, Colorado, 80920, United States
Velocity Clinical Research, Seattle
RECRUITING

Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.